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The HIV Epidemic: a Global Problem
The World Health Organization has estimated
that 22.6 million people are infected with human
immunodeficiency virus (HIV) as of mid-1996 (1).
The highest prevalence of HIV occurs in parts of
Asia and sub-Saharan Africa. In 1995, HIV-
associated illnesses caused the deaths of 1.3
million people, including 300,000 children under
5 years of age. No protective vaccine or cure is
available, and while prevention methods are
reducing incidence in some countries, HIV
disease is expected to increase. Earlier HIV infec-
tion diagnosis, inhibition of ongoing HIV replica-
tion with antiretroviral therapy (in industrialized
countries), and prevention and treatment of
opportunistic infections and cancers delay the
onset of AIDS and increase the life expectancy
of HIV-infected persons.
An Overview of Host Genes and HIV
Infection
Since the early years of the HIV epidemic,
significant differences in the rate of disease
progression have been observed in longitudinally
followed HIV-infected persons. The role of genes
of the human leukocyte antigen (HLA) system in
determining the course of disease has been
examined by using such measures as the CD4+ cell
count or the length of time between HIV infection
and AIDS (2-6). Several HLA genes or haplotypes
appear to influence disease progression, although
the effects are complex and may depend on
interactions with other host genes.
Studies of the effect of host genes on sus-
ceptibility to HIV infection were facilitated by the
identification of persons who were persistently
exposed to HIV but remained uninfected (7-12).
Before the discovery of the role of chemokine
receptor gene polymorphism in HIV infection,
only genes of the HLA system were thought to
protect against HIV infection. For example, cer-
tain distributions of HLA class I alleles were
observed in uninfected female commercial sex
workers in Africa (13,14) and Thailand (11), who
had been highly exposed to HIV; additional class
I and II alleles that may be associated with
remaining uninfected have been identified (6).
Several mechanisms, some related to cytotoxic T-
cell function, have been suggested to explain
these findings (7,10,11,15).
Non-HLA genetic factors also influence sus-
ceptibility to HIV infection and the course of HIV
disease. In 1996 and 1997, studies confirmed the
protective role of homozygosity for a 32 base
pair (bp) deletion in the chemokine receptor
gene, CCR5 (D32 CCR5), against HIV infection
(9,12,16-19). Until recent reports of HIV infection
in three persons homozygous for the 32 bp CCR5
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deletion (20-22), no cases of HIV infection had
been reported in studies of more than 60 persons
homozygous for the CCR5 32 bp deletion. Pre-
sence of one copy of the deleted CCR5 gene also
influences the course of disease as the onset of
AIDS occurs later for some heterozygous per-
sons than for those homozygous for the wild
type CCR5 (12,17-19,23). The discovery of the
role of CCR5 alleles has prompted studies of
the possible role of many other host genes in
HIV infection (24-26).
What Are Chemokine Receptors?
Chemokine receptors are cell surface proteins
that bind small peptides called chemokines (27).
Chemokines can be classified into three groups
based on the number and location of conserved
cysteines: C, CC, and CXC. Chemokine receptors
are grouped into families on the basis of the
chemokine ligands they bind: CC, CXC, or both
(27; Table 1). Some receptors are promiscuous,
while others are selective in terms of ligand
binding. The receptors are widely distributed on
hematopoietic and other cells, but the Duffy
antigen of erythrocytes (DARC) is the only
member expressed on cells of erythroid lineage.
Several human chemokine receptors have been
classified as such on the basis of similarity of
gene sequences and predicted protein structures,
but their ligands have not been identified
(orphan receptors). Among these is the recently
identified TER1 gene (28).
The characteristic feature of all chemokine
receptors is a serpentine 7 transmembrane-span-
ning domain structure, which is shared with
other receptors; e.g., the rhodopsin and the
thyrotrophin receptors (Figure 1). Extracellular
portions are involved in chemokine binding,
while intracellular portions are involved in cell
signaling. The effect of receptor-ligand interac-
tions is usually mediated through G-protein
coupled interactions; results in alterations in cell
Table 1. Human chemokine receptors
Chromo-
Receptors Predominant expression/  some GenBank
(Old names)a Ligands Tissue distribution Pathogensb location Acc. #
C-C CXC
chemokines chemokines
CC Receptors
CCR1 MIP-1a, ß, monocytes, T cells 3p21 L10918
(CC CKR1) RANTES,
MCP-3
CCR2A MCP-1 T cells, basophils 3p21 U03882
(MCP-1Ra) monocytes,
CCR2B MCP-1, 3, 4 HIV-1 (NSI) U03905
(MCP-1Rb)
CCR3 Eotaxin, eosinophil, basophils, microglial HIV-1 3p21 U28694
(CKR3) RANTES, cells, and possibly monocytes; (NSI)
MCP-2,3,4 little expression in peripheral
blood T-lymphocytes or dendritic cells
CCR4 TARC basophils, T cells 3p24 X85740
CCR5c RANTES, monocytes, dendritic cells, HIV-1, 3p21 U57840
(CC CKR5) MIP-1a, ß microglial cells, T cells (NSI) HIV2
CXC Receptors
CXCR1 IL-8 neutrophils, NK cells 2q35 M68932
(IL-8 RA)
CXCR2 IL-8, MGSA, M73969
(IL-8 RB) gro-a,
NAP-2, IP-10,
ENA-78, Mig
CXCR3 IP-10, Mig activated T cells X95876
CXCR4 SDF-1 wide: CD4+ and CD4- cells, HIV-1 (SI) 2q21 M99293
(Fusin, LESTR, monocytes, macrophages, HIV-2
HUMSTR) dendritic cells, B cells; other
tissues, e.g., brain, lung, spleen263 Vol. 3, No. 3, July–September 1997 Emerging Infectious Diseases
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function such as activation, motion, or migra-
tion, usually along a chemokine concentration
gradient; and varies depending on the chemokine
bound and the cell type (27).
Some chemokine receptors have a role in
infectious disease susceptibility or pathogenesis.
Several of the CC or CXC receptors are used by
HIV-1 or HIV-2 as entry cofactors (Table 1). DARC
serves as a cofactor for entry of Plasmodium
vivax into erythrocytes (29); and as is the case
with the 32bp-deleted CCR5 and HIV, resistance
to P. vivax malaria is associated with lack of
DARC expression (29), probably due to polymor-
phism of the DARC gene promoter (30). Several
viruses (Epstein-Barr virus, cytomegalovirus,
and  Herpes virus samiri) contain functional homo-
logues of human chemokine receptors, which
suggests that the viruses may use these receptors
to subvert the effects of host chemokines (27).
They may also serve as HIV entry cofactors for
human cells, as observed for HCMV-US28 (31).
Chemokine Receptors and HIV Infection
The first clue that chemokine-related events
were important in HIV pathogenesis came from
work in R. Gallo’s laboratory, which showed that
high levels of chemokines could inhibit HIV
replication in vitro (32). Then a cohort of highly
exposed, HIV-negative men had high circulating
levels of several chemokines, such as RANTES,
MIP-1a, and MIP-1ß (8). These data led to the
hypothesis that chemokines might prevent HIV
infection by binding to the elusive HIV entry
cofactor. Since the discovery of CD4 in the 1980s
as an HIV receptor, it had become apparent that
other factors were required for HIV to enter cells.
For example, mouse cells expressing CD4 could
not be infected with HIV (33). Using a novel
cloning strategy, E. Berger and colleagues first
demonstrated in May 1996 that CXCR4, a
chemokine receptor for which no ligand had yet
been determined, was an entry cofactor for T-cell
tropic or syncytium-inducing (SI) viruses (34).
CC/CXC Receptor
DARC RANTES, IL-8, MGSA, endothelial cells, Plasmo- 1 U01839
(Duffy antigen) MCP-1, gro-a etc. erythrocytes dium vivax
TARC etc.
Others d
STRL33 ND ND lymphoid tissues and HIV-1 3 U73529
activated T cells
HCMV-US28 MIP-1a, ß, fibroblasts infected with CMV HIV-1 N/A X17403
RANTES
ChemR1 ND ND T lymphocytes, 3p21-24 Y08456
polymorphonuclear cells
CMKBRL1 ND ND neutrophils, monocytes, brain, 3p21 U28934
liver, lung, skeletal muscles
TER1 ND ND thymus, spleen 3p21 U62556
V28 ND ND Neural and lymphoid tissue 3p21 U20350
D2S201E ND ND wide, including cells 2q21 M99293
of hemopoietic origin
BLR1 ND ND B lymphocytes X68149
EBI1 ND ND B lymphocytes L08176
GPR1,2,5 ND ND ND L36149
a New nomenclature for CC and CXC chemokine receptors was adopted at the Gordon Research Conference on Chemotactic
Cytokines, June 23–28, 1996.  bPathogens using this receptor for infection.   c The 32bp deleted allele of CCR5 has been referred to
as CCR5-2 (19). dChemokine receptor-like genes whose predicted proteins have 7 transmembrane domains.
Abbreviations: BLR1, Burkitt’s lymphoma receptor-1; CMKBRL1, Chemokine ß receptor like-1; DARC, duffy antigen/receptor for
chemokines; EBI1, Epstein-Barr virus-induced receptor; ENA78, epithelial-derived neutrophil-activating peptide-78; GPR, G
protein coupled receptor; gro, growth related gene product; HCMV, human cytomegalovirus; HUMSTR, human serum
transmembrane segment receptor; IL, interleukin; IP-10, interferon-gamma inducible 10kD protein; LESTR, leukocyte-expressed
seven-transmembrane-domain receptor; MCP, monocyte chemotactic protein; Mig, monokine induced by  interferon gamma; MIP,
macrophage inflammatory protein; NSI, non-syncytium inducing; N/A, not applicable; NAP-2, neutrophil-activating protein-2; ND,
not determined; RANTES, regulated on activation, normal T cell expressed and secreted; SDF-1, stromal cell-derived factor-1;
STRL33, seven transmembrane-domain receptor from lymphocyte clone 33;TARC, thymus and activation regulated chemokine.
Table 1. Human chemokine receptors (continued from p. 2)
Chromo-
Receptors Predominant expression/  some GenBank
(Old names)a Ligands Tissue distribution Pathogensb location Acc. #
C-C CXC
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Figure 1. Predicted structure and amino acid sequence of
CCR5. The typical serpentine structure is depicted with
three extracellular (top) and three intracellular (bottom)
loops and seven transmembrane (TM) domains. The
shaded horizontal band represents the cell membrane.
Amino acids are listed with a single letter code. Residues
that are identical to those of CCR2b are indicated by dark
shading, and highly conservative substitutions are
indicated by light shading. Extracellular cysteine
residues are indicated by bars, and the single N-linked
glycosylation consensus site is indicated by an asterisk.
Reprinted and modified with permission from the
authors and Cell (39). Copyright (1996) Cell Press.
NSI viruses (which appear to be the viruses
transmitted in vivo) tend to be CCR5 tropic
(33,34,36-39). However, some primary SI viruses
can use either CXCR4 or CCR5 (42), and some
may use both coreceptors, as well as CCR2b or
CCR3 (39). When classified based on chemokine
receptor use, HIV types are independent of their
genetic relatedness (43).
The exact mechanism by which HIV inter-
acts with CXCR4 or CCR5 and by which this
interaction, together with CD4 binding, leads to
virus entry has not been clearly defined (44). It
appears to involve the interactions of the V3 loop
and other parts of the outer envelope protein
gp120 (45-47) with extracellular domains of CCR5
or CCR2b (48,49) and may involve multistep
Shortly before this, Samson et al. had cloned
CCR5 (then known as CC-CKR5) and shown that
its ligands included RANTES, MIP-1a, and MIP-
1ß (35). These data encouraged several groups to
examine the role of CCR5 in HIV entry, and within
weeks of the CXCR4 publication, five additional
publications reported CCR5 and CCR3 as HIV
entry cofactors for macrophage-tropic or non-
syncytium-inducing (NSI) viruses (33,36-39) and
CCR3 and CCR2b as entry factors for dual tropic
HIVs (38,39). Recent studies of brain-derived
microglial cells have shown that CCR5 and CCR3
permit entry of HIV into these cells (40).
The tropism of HIV strains appears to be
determined in part by the way they use chemo-
kine receptors (Table 1, Figure 2). In peripheral
blood, although both T cells and monocytes
express CXCR4 and CCR5 (41), HIV strains that
use CXCR4 tend to infect predominantly T cells,
while strains that use CCR5 infect T cells and
monocytes. This tropism correlates with the
ability of the virus to induce syncytia in T-cell
lines. SI viruses (often present late in the course
of HIV infection), tend to be CXCR4 tropic, while
Figure 2. Chemokine receptors and cell tropism of HIV.
Three cell types are illustrated, an in vitro passaged T-
cell line (Tl), a monocyte/macrophage (M), and a
circulating T-cell (T).  T-cell lines express CXCR4 but
not CCR5; macrophages and circulating peripheral
blood T-cells express both receptors, although the
amounts of CXCR4 are lower on macrophages (as
indicated by the small CXCR4 symbol). M-tropic HIV,
because of certain envelope amino acid sequences,
binds to CCR5 and can enter both macrophages and
circulating T cells. T-tropic HIV preferentially binds
CXCR4 and enters T cells or T-cell lines. After binding
to the chemokine receptor and to CD4, the viruses enter
by fusion with the cell membrane. Cells with the 32bp
deleted form of CCR5 do not express cell surface CCR5,
and, although M-tropic HIV can bind CD4, it cannot
enter the cell. If the cells express CXCR4, they can still
be infected with T-tropic viruses (not shown).  Note that
this figure does not depict the actual size relationships
of the proteins, cells, or viruses.
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interactions with CD4, the chemokine receptor,
and other cell surface components (50). Chemo-
kines may inhibit HIV entry through receptor
blockade, desensitization, sequestration, or interna-
lization; through alterations in receptor affinity;
or by inhibiting postbinding steps (51), such as
phosphorylation, through G-coupled mechanisms.
Chemokine Receptor Gene Polymorphism
and Susceptibility to HIV Infection
In 1995 and 1996, researchers at the Aaron
Diamond AIDS Research Center began studies of
highly HIV-exposed seronegative men whose
cells produced high levels of chemokines in vitro
(8,52). Cells from several of these men were not
infectable with primary or NSI type viruses, but
were infectable with SI viruses (52). These data
suggested some protective mechanism related to
the CCR5 rather than to the CXCR4 receptor
because of the chemokine ligand profile of the
CCR5 receptor (Table 1) and stimulated studies
that led to the cloning and restriction digestion of
CCR5 in these persons (52). The novel deletion of
32bp in CCR5 reported by Liu et al. (9) in August
1996, to be present in three of the 15 HIV-exposed
but seronegative men was also independently
reported in September by Samson et al. (16) and
Dean et al. (17; Table 2). In these studies, the
distribution of homozygosity and heterozygosity
of the deleted allele, in small and large cross-
sectional or prospective studies of HIV-unexposed,
-exposed, or -infected persons (mainly European
or North American Caucasians) strongly sup-
ported the protective effect of  the deletion. Since
these initial observations, several studies of
other populations have reported the same
finding: an enrichment of the homozygous D32/
D32 CCR5 genotype in highly HIV-exposed per-
sons who remain uninfected (12,18,19; Table 2).
In persons with well-documented HIV exposure,
the prevalence of homozygosity for the D32/D32
CCR5 genotype increases with increasing HIV
exposure (12), the wild type and D32 CCR5 alleles
(referred to by some as CCR5-1 and CCR5-2 [19])
can be easily detected by polymerase chain
reaction (PCR) techniques, with or without enzy-
matic digestion (9,12,16,17), or more recently, by
heteroduplex studies (19). An example of the
results of a PCR followed by restriction digestion
is given in Figure 3. Persons who are homozygous
for the wild type CCR5 (W) or the allele with the
32 bp deletion (D32) or heterozygous for both
alleles can be easily distinguished because the
deleted fragment reduces the size of the
amplified product (Figure 3).
The 32 bp deletion occurs at a site of a repeat
motif in the CCR5 gene (16; Figure 4) and results
in a frame shift in the coding sequence that pro-
duces a defective CCR5, which is not expressed
on the surface of cells (Figures 2 and 5). The dele-
tion results in the loss of three of the seven trans-
membrane domains, two of the three outer loops,
and the intracellular signaling domain (Figure 5).
Does the CCR5 32 Bp Deletion Provide
Absolute Protection Against HIV
Infection?
The genetic link to remaining HIV-negative
in spite of continued HIV exposure was the
subject of much discussion during the summer
and fall of 1996. Was the protection absolute?
Who should be tested for the gene? Would
persons told they were homozygous for the dele-
tion engage in high-risk behavior more frequently?
Although at that point no one homozygous for the
deletion had been found HIV-positive, the fact
that CXCR4 gene and several other chemokine
receptors could mediate HIV entry suggested
caution in assuming that persons with the CCR5
D32/D32 genotype would be absolutely resistant
to HIV infection. Since then, three HIV-
infected persons with this genotype have been
reported (20-22; Table 2); for one, the mode of
Figure 3.  Differentiation of CCR5 genotypes by gel
electrophoresis.  Band patterns of persons with
homozygous wild type (W/W), homozygous 32 bp deletion
(D32/D32) or heterozygous W/D32 CCR5 genotypes are
shown.  PCR amplification of the C-terminal of the CCR5
gene, subsequent digestion with the EcoRI restriction
enzyme, and agarose gel electrophoresis of the digested
DNA yield a 182 bp band for the wild type CCR5 gene, a
150 bp band for the  32 allele, and both bands in the case
of a heterozygous person.
W/W
182 bp
150 bp
W/D D D D D32 D D D D D32/D D D D D32 Band
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Table 2. Population studies of CCR5 genotypes
HIV aCCR5 Genotypes D32 allele
Author Population Ethnicity Status No.  % (No.)  freq. (%)
W/W W/ D32  D32/D 32
Liu et al. (9) High-risk, USA Caucasian Neg     15 80.0 (12) 0 (0) 20.0  (3) 0.200
General, USA Caucasian Neg   122 80.3 (98) 19.7 (24) 0 (0) 0.098
General,  S. Amer. Venezuelan Neg     46 100 (46) 0 (0) 0 (0) 0
Samson General, Europe Caucasian Neg   704 82.7 (582) 16.2 (114)  1.1 (8) 0.092
et al. (16) General, Asia Japanese Neg   248 100 (248) 0 (0)  0 (0) 0
General, Africa Ctrl/W. African Neg   124 100 (124) 0 (0)  0 (0) 0
AIDS clinics, Paris Caucasian Pos   723 89.2 (645) 10.8 (78)  0 (0) 0.054
Dean High-risk, USA Mixed Neg   883 81.9 (724) 15.6 (138)  2.4 (21) 0.10
 et al.b(17) High-risk, USA Mixed Pos 1883 85.9 (1618) 14.0 (264)  0.0005 (1) 0.071
High-risk, USA African-Amer. Mixed   620 96.6 (599) 3.4 (21)  0 (0) .017
High-risk, USA Caucasian Mixed 1250 0.115
Low-risk, USA Caucasian Mixed   143 0.080
Huang High-risk, USA Caucasian Pos   461 79.8 (368) 20.2 (93) 0 (0) 0.101
et al.(12) High-risk, USA Caucasian Neg   446 78.0 (348) 16.7 (82) 3.6 0.128
Blood donors, USA Caucasian, 95% Neg   637 85.2 13.3 1.4 0.08
General, Black Mixed   137 100 0 (0) 0 (0) 0
Africa/Haiti
General, Asia China/Thai/ Mixed   191 100 0 (0) 0 (0) 0
other
Michael High-risk, USA Mixed Pos   406 87.5 (348) 14.3 (58) 0 (0) 0.071
 et al.(18) High-risk, USA Mixed Neg     21 71.4 (15) 9.5 (2) 19.1 (4) 0.238
Intermed.-risk, USA Mixed Neg   240 78.3 (188) 20.4 (49) 1.3 (3) 0.115
Biti High-risk, Caucasian Pos   265 N/Ac N/A 0.004 (1) N/A
 et al. (20) Australia
Theodoru High-risk, Pos   412 N/A N/A 0.002 (1) N/A
et al. (22) Europe
Eugenolsen High-risk, Denmark Caucasian Neg     35 74 (26) 20 (7) 6 (2) 0.157
 et al. (23)
High-risk, Denmark Caucasian Pos     99 78 (77) 22 (22) 0 0.111
Blood  donors, Caucasian Neg     37 73 (27) 24 (9) 3 (1) 0.149
Denmark
Zimmerman Blood donors, Caucasian Neg   387 77.5 (300) 21.7 (84) 0.8 (3) 0.116
 et al. (19) N. America African-Am. Neg   294 94.2 (277) 5.8 (17) 0 (0) 0.29
Hispanic Neg   290 92.8 (269) 6.9 (20) 0.3 (1) 0.38
Asian Neg   164 99.4 (163) 0.6 (1) 0 (0) 0.003
Native Amer. Neg     87 83.9 (73) 12.6 (11) 3.4 (3) 0.098
Blood donors, Tamil Neg     46 100 (46) 0 (0) 0 (0) 0
India
Blood donors, Black Neg     40 100 (40) 0 (0) 0 (0) 0
W. Africa
High risk, USA Caucasian Pos   614 77.4 (475) 22.6 (139) 0 (0) 0.113
High risk, USA African-Amer. Pos     86 97.7 (84) 2.3 (2) 0 (0) 0.012
High risk, USA Hispanic Pos     45 93.3 (42) 6.7 (3) 0 (0) 0.033
High risk, USA Caucasian Neg   111 73.9 (82) 21.6 (24) 4.5 (5) 0.153
High risk, USA African-Amer. Neg       2 50.0 (1) 0 (0) 0.250
High risk, USA Hispanic Neg     12 91.7 (11) 8.3 (1) 0 (0) 0.042
a CCR5 genotypes: W/W, homozygous wild type; W/ D32, heterozygous wild type/32bp deletion;  D32/D 32, homozygous for the
32 bp deletion.
b Numbers updated to include additional Multicenter Hemophilia Cohort Study patients studied by O’Brien et al. (21) and
Dean et al. (pers .comm.).
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transmission was most likely blood products (21),
while the only reported exposure risk for the
other two was homosexual behavior (20,22).
Sequences isolated from these persons suggested
the SI virus phenotype, i.e., viruses that most
likely used CXCR4 as entry cofactors (21; R.
Ffrench, pers. comm.). As several other non-
CCR5 receptors (CCR3 and CCR2b) are also HIV
entry cofactors, even non-SI viruses might be
transmissible in vivo in persons homozygous for
the CCR5 32 bp deletion.
Thus, HIV entry by non-
CCR5 dependent mechanisms
can occur in vivo, and persons
who have the CCR5 D32/D32
genotype are not absolutely
protected.
Does CCR5 Gene
Polymorphism Determine
All Resistance to HIV?
The highest reported prevalence of homo-
zygosity for the  D32 CCR5 allele deletion in
persons highly exposed to HIV but uninfected is
33% (9,12). However, most (96% according to one
estimate [19]) highly exposed HIV-seronegative
persons are not homozygous for the D32 CCR5
allele. Moreover, among exposed but persis-tently
HIV-seronegative per-sons in Africa and Thailand,
no one positive for the D32 CCR5 allele has been
found (CDC unpub. data; S. Rowland-Jones, F.
Plummer, pers. comm.). These data suggest that
many mechanisms may contribute to remaining
seronegative despite high HIV exposure: chemo-
kine-related mechanisms, such as altered CCR5
levels on the cell surface (53) or the level of
circulating chemokines; other immune system
genes, such as those of the HLA system
(10,11,14); and immune responses, such as those
of cytotoxic T cells (7,15). The relative importance
of these mechanisms in populations with dif-
fering modes of exposure or genetic backgrounds
needs to be elucidated.
CCR5 Polymorphism and Its Interaction
with Other Factors in the Course of HIV
Disease
Several large studies of the effect of CCR5
genotypes on the course of HIV disease have been
published (Table 2). Dean et al. examined the
course of HIV (time to AIDS) in several U. S.
populations with different exposure to HIV
(homosexuals, intravenous drug users, persons
with hemophilia) and found that persons with
one copy of the deleted CCR5 gene had a delayed
(approximately 2 years longer) progression to
AIDS when compared with those with the
homozygous wild type genotype (17). Similar
findings have been reported (19,23) in Caucasian
HIV-positive homosexual men. Another study of
HIV-positive homosexuals did not find such a
striking effect of heterozygosity, although pro-
gression to AIDS was again slowed (12). One clue
Figure 4. Partial CCR5 gene and amino acid sequence with 32 bp deletion.
Nucleotide sequence of the CCR5 gene surrounding the deleted region, and
translation into the normal receptor (top lines) or the truncated mutant (D 32
CCR5, bottom lines).  The 10-bp direct repeat is represented in bold italics and
the deleted nucleotides are represented in noncapitalized font.
Figure 5. Predicted structure and amino acid sequence of
the mutant form of human CCR5. The mutant protein
lacks the last three transmembrane segments of CCR5,
as well as the regions involved in G-protein coupling.  The
transmembrane organization is given by analogy with
the predicted transmembrane structure of the wild-type
CCR5, although the correct maturation of the mutant
protein up to the plasma membrane has not been
demonstrated. The shaded horizontal band represents
membrane (s) of intracellular organelles. Amino acids
represented in italic and dark shading correspond to
unnatural residues resulting from the frame shift caused
by the deletion. Figures 4 and 5 reprinted and modified
with permission from the authors and Nature (16)
Copyright (1996) Macmillan Magazines Ltd.
CCR5  F  P  Y  S  Q  Y  Q  F  W  K  N  F  Q  T  L  K  I  V  I  L  G  L  V  L  P 
      TTTCCATACA gtcagtatcaattctggaagaa tttccagaca TTAAAGATAGTCATCTTGGGGCTGGTCCTGCCG
Dccr5 F  P  Y                                  I  K  D  S  H  L  G  A  G  P  A  
CCR5  L  L  V  M  V  I  C  Y  S  G  I  L  K  T  L  L  R  C  R  N  E  K  K  R 
      CTGCTTGTCATGGTCATCTGCTACTCGGGAATCCTAAAAACTCTGCTTCGGTGTCGAAATGAGAAGAAGAGG
Dccr5 A  A  C  H  G  H  L  L  L  G  N  P  K  N  S  A  S  V  S  K  *           
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to the varying effects of the heterozygous CCR5
genotype on progression to AIDS in different
groups comes from another U. S. study of male
homosexuals, in which men with one copy of the
D32 CCR5 genotype had delayed progression to
AIDS, particularly if their circulating viruses
were of the NSI phenotype (18). Paradoxically,
once AIDS is diagnosed, persons with one copy of
D32 CCR5 may have a more rapid disease course.1
Thus, the effect of the CCR5 genotype on disease
progression may depend on the phenotype and
chemokine receptor use of circulating viruses.
The finding that microglial cells can be infected
with HIV through CCR3- or CCR5-dependent
mechanisms (40) also suggests that the clini-
cal spectrum of HIV disease may also depend
on the CCR5 genotype.
Thus, complex interactions between virus
and host chemokine receptor genotype and virus
and cell chemokine receptor phenotype exist.
Studies to elucidate the interaction of these
genotypes with each other, with virus phenotypes,
and with other factors that influence the course of
HIV disease are ongoing (24,25). Preliminary
data from the Multi Center AIDS Cohort Study
suggest that the effect of CCR5 and HLA geno-
type on survival or disease course are inde-
pendent and that the effect of HLA on disease
outcomes may be greater than the effect of CCR5
genotype (54).
Population Studies of CCR5 Genotypes
The distribution of the 32bp deletion in
different populations is summarized in Table 2.
Among Caucasians in North America or Europe,
the prevalence of homozygosity for the 32 bp
deletion is approximately 1%, and 10% to 20% are
heterozygous. In smaller numbers of non-Cau-
casians, heterozygosity is found in approximately
6% of African-Americans, 7% of Hispanics, 13% of
Native Americans, and fewer than 1% of Asians
(17,19; CDC, unpub. data). Several studies of
non-Caucasian populations including persons
from parts of Africa (Zaire, Burkina Faso, Came-
roon, Senegal, Benin, Uganda, Rwanda, Kenya,
Malawi, Tanzania, Sierre Leone) (12,16,19),
Haiti (12), parts of Asia (Thailand, India, China,
Korea, Japan, the Philippines) (12,16,19; CDC,
unpub. data), and Venezuela (9) have not found
the 32 bp deletion among the HIV-infected or -
uninfected persons tested (Table 2). One
additional study (of more than 3,000 persons)
found similar global distributions of CCR5
genotypes (and noted a decreasing frequency
from north to south in Europe and Asia).2
Other Chemokine Receptor
Polymorphisms
Several other point mutations in CCR5 have
been observed (17), but their population preval-
ence and their role in HIV infection or disease
progression have not been reported. No poly-
morphisms in CXCR4 have been reported to date.
CCR3 has two alleles (S or T at position 276) (55-
57), and similarly, the population prevalence of
these alleles and their role in HIV infection have
not yet been determined.
Implications for Management and
Understanding of the Global HIV Epidemic
The discovery of the role of chemokine
receptors as coreceptors, along with CD4, for HIV
entry has led to a burgeoning of public and
private research in HIV pathogenesis, new
therapies, and new approaches to vaccines
(52,58). For example, in addition to the classi-
fication of HIV types on the basis of genetic or
neutralization phenotype relatedness, a new
virus classification made on the basis of their
receptor use has emerged. New therapies based
on receptor mimics, receptor ligands, chemokines,
or chemokine analogs are being developed and
tested in vitro. Genetic engineering with chemo-
kine receptors is being used to develop animal
models for HIV transmission and disease
progression. And, in the arena of vaccines, a new
concept has developed: the induction of high
levels of HIV-blocking chemokines such as
RANTES, MIP-1a, and MIP-1ß as desirable
properties of an HIV vaccine.
New treatments and prevention measures
for HIV raise ethical, social, and legal issues that
also relate to a number of other infectious and
chronic diseases (e.g., malaria, breast cancer,
and diabetes) as new genes influencing the risk
for these diseases are discovered. Should all
1Garred P, Eugen-Olsen J, Iversen AKN, Benfield TL, Svejgaard A, Hofmann, B, the Copenhagen AIDS Study Group. Dual effect
of CCR5 D32 gene deletion in HIV-1-infected patients. Lancet 1997; 349:1884.
2Martinson JJ, Chapman NH, Rees DC, Lui Y-T, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion [letter].
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persons at risk for HIV infection be tested for
CCR5 gene polymorphism? Should persons
homozygous for the D32 CCR5 genotype receive
specific counseling regarding their risk for HIV
and other sexually transmitted infections? If a
person is heterozygous and infected with HIV,
should HIV treatment be altered? Could
knowledge of one’s genotype favorably or
unfavorably influence health insurance, life
insurance, or employment opportunities? As a
result of these questions, educational materials
have become available for the public and public
health professionals.3
Another finding that provoked discussion
was the uneven distribution of the genotype
across geographic and racial groups. One hypo-
thesis was that some previous epidemic, restric-
ted to Europe, had led to a survival advantage
among persons homozygous or heterozygous for
the CCR5 D32 genotype and had resulted in a
concentration of the CCR5 D32 genotype in
persons of European ancestry. The “black death”
of Northern Europe (1347-1350) and other large
epidemics have been used as examples (59,60).
Thus, certain populations appear to have an
increased survival advantage in the new HIV
epidemic. Conversely, populations with lower
prevalence of the D32 CCR5 genotype might be
expected to have a higher prevalence of HIV
infection or a more rapid course of the epidemic.
In the United States,  a greater risk for HIV
infection has been found among African-
Americans than among Caucasians, when known
risk factors, including social class, were con-
trolled (61). The prevalence of the D32 CCR5
allele is lower in African-Americans than in
Caucasians. While increasing HIV prevalence in
parts of Asia and Africa may be attributed to
social and demographic factors, as well as
differences in the phenotype of circulating
viruses (62), the racial distribution of HIV risk
raises the possibility that differences in the
distribution of the D32 CCR5 allele or other
heritable host factors might influence the rate
of transmission or the speed of the epidemic in
different racial groups.
Conclusions
These findings have defined a new role for a
gene that normally controls cell migration; have
identified new alleles of the gene that determines
whether someone becomes infected with HIV and
how the disease progresses once infection has
occurred; and have identified several other new
HIV-receptors that mediate viral entry into dif-
ferent cell types. The findings have precipitated
new classifications of HIV phenotypes by cell
tropism and receptor use and opened new areas
for drug and vaccine development. These findings
have also enhanced other research: studies of host
factors affecting the acquisition and clinical
course of infectious diseases, the differential
distribution of genetic characteristics in popu-
lations and their potential effects on health status,
the translation of genetics research into public
health measures, and the social implications of
genetic differences affecting illness and death
caused by infectious and other diseases.
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